A surface enhanced Raman scattering based colloid nanosensor for developing therapeutic drug monitoring.
Competitive reactions
Erlotinib
Gold nanoparticles
SERS
Therapeutic drug monitoring
Journal
Journal of colloid and interface science
ISSN: 1095-7103
Titre abrégé: J Colloid Interface Sci
Pays: United States
ID NLM: 0043125
Informations de publication
Date de publication:
01 Jan 2019
01 Jan 2019
Historique:
received:
04
06
2018
revised:
26
07
2018
accepted:
28
08
2018
pubmed:
8
9
2018
medline:
2
2
2019
entrez:
8
9
2018
Statut:
ppublish
Résumé
Competitive reactions, on the surface of plasmonic nanostructures, allow exploiting SERS signals for quantitative Therapeutic Drug Monitoring. As an example, the concentration of Erlotinib, an anti-EGFR small molecule, used for the treatment of non-small cell lung and pancreatic cancer, is determined. The numerous side effects and the variability of patient responses make Erlotinib a good candidate for monitoring. The new SERS based sensor can estimate Erlotinib down to nanomolar concentration and is based on the chemical reaction of the drug and of a competitor SERS reporter on the surface of gold nanostructures. Colloid solutions of naked gold nanoparticles obtained by laser ablation in solution were used for obtaining nanostructures with very efficient hot spots for SERS and with a clean surface for chemistry. Detection of the drug in the nanomolar concentration range is shown to be possible also in spiked plasma samples.
Identifiants
pubmed: 30193149
pii: S0021-9797(18)31026-9
doi: 10.1016/j.jcis.2018.08.107
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Colloids
0
Gold
7440-57-5
Erlotinib Hydrochloride
DA87705X9K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-626Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.